ERBB2 and breast carcinoma: While molecular targeted agents such as trastuzumab and pertuzumab have shown limited efficacy in HER2-low breast cancer subtype23,24, small molecule tyrosine kinase inhibitors (TKIs) are promising in individuals with HER2 mutations within the advanced HR+/HER2− subgroup25.